Publicaciones en colaboración con investigadores/as de Amiri Hospital (19)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2022

  1. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

  2. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180

    Computer methods and programs in biomedicine

2021

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

  2. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2020

  1. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

2018

  1. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

    Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652

2017

  1. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1346-1357

  2. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405

  2. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, Núm. 12, pp. 1343-1349

  3. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

    Multiple Sclerosis, Vol. 22, Núm. 4, pp. 520-532

2015

  1. BREMSO: A simple score to predict early the natural course of multiple sclerosis

    European Journal of Neurology, Vol. 22, Núm. 6, pp. 981-989

  2. Defining reliable disability outcomes in multiple sclerosis

    Brain, Vol. 138, Núm. 11, pp. 3287-3298

  3. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS

    PLoS ONE, Vol. 10, Núm. 6

  4. Predictors of disability worsening in clinically isolated syndrome

    Annals of Clinical and Translational Neurology, Vol. 2, Núm. 5, pp. 479-491

2014

  1. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

    Annals of Neurology, Vol. 76, Núm. 6, pp. 880-890

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

    Brain, Vol. 136, Núm. 12, pp. 3609-3617